Luye Pharma Announces 2026 Interim Results
Reporting 24.8% growth of profit attributable to shareholders
Setting the bar for Chinese pharma with end-to-end global CNS capabilities
Shanghai, August 30, 2026 -- Luye Pharma Group (2186.HK) today announced its 2026 interim results and latest developments.
During the ...
August 31,2026
Luye Pharma Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R ...
Shanghai, August 5, 2026 — Luye Pharma Group today announced the successful completion of a U.S. bridging clinical trial of its in-house developed new molecular entity, LY03015. The results support the commencement of the upcoming efficacy clinical trial of the investigational drug in ...
August 05,2026
16
2026-06
Luye Pharma Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
20
2026-04
Luye Pharma Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015
15
2026-04
Luye Pharma Announces First Subject Enrolled in China Phase Ⅱ Clinical Trial of LY03017 (5-HT2AR/5-HT2CR) for Alzheimer’s Disease-related Psychosis
08
2026-04
First Subject Enrolled in Phase Ⅱ Clinical Trial of Luye Pharma’s TAAR1/5-HT2CR-targeted Investigational Drug for Treating Schizophrenia
01
2026-04
Luye Pharma Announces 2025 Financial Results
13
2026-03
Luye Pharma Forms Strategic Partnership with Sinopharm Group and Sinopharm CNCM to Commercialize Mimeixin® and Other Products
08
2026-01
NMPA Accepts the NDA for Luye Pharma’s Ruoxinlin® for the New Indication of Generalized Anxiety Disorder
24
2025-12
Luye Pharma Grants Nhwa Exclusive Rights to Commercialize Three Long-Acting Injectable Antipsychotics in the Chinese Mainland
07
2025-12
Luye Pharma’s Five New Products Included in China’s 2025 National Reimbursement Drug List or Commercial Insurance Innovative Drug List
24
2025-11
Luye Pharma Receives FDA Clearance of IND Application for Its Next-generation 5-HT2AR Inverse Agonist/5-HT2CR Antagonist LY03017
